ANGO241220C2500
- 5.00
- 0.000.00%
AngioDynamics Newsroom
AngioDynamics, Inc. (NASDAQ:ANGO) Stock Catapults 29% Though Its Price And Business Still Lag The Industry
AngioDynamics Analyst Ratings
ANGO Stock Up Post FDA Nod for Prostate Tissue Ablation With NanoKnife
H.C. Wainwright Maintains AngioDynamics(ANGO.US) With Buy Rating, Maintains Target Price $14
Institutional Investors Have a Lot Riding on AngioDynamics, Inc. (NASDAQ:ANGO) With 74% Ownership
AngioDynamics Shares at 52-Week High After FDA Clears NanoKnife
Express News | AngioDynamics Shares up 13.9% on US FDA Clearance of Prostate Cancer Treatment Device
The FDA Has Granted 510(k) Clearance For AngioDynamics' Nanoknife System For Prostate Tissue Ablation
AngioDynamics Receives FDA Clearance for The NanoKnife System for Prostate Tissue Ablation
Express News | AngioDynamics Receives FDA Clearance for the Nanoknife® System for Prostate Tissue Ablation
NARI Stock Likely to Gain Following Reimbursement Approval in Japan
AngioDynamics Shareholder Approvals and Director Elections
Fresenius Medical Q3 Earnings Beat Estimates, Operating Margin Rises
Tempus Stock Declines Despite Q3 Earnings & Revenues Beat Estimates
Wall Street Analysts Believe AngioDynamics (ANGO) Could Rally 94.32%: Here's Is How to Trade
Investors in AngioDynamics (NASDAQ:ANGO) Have Unfortunately Lost 77% Over the Last Three Years
AngioDynamics Stock Plunges 13.8% in Three Months: What's Next?
ANGO Stock Rises Following the Receipt of CPT Category I Code for IRE
CCORF Maintains AngioDynamics(ANGO.US) With Buy Rating, Maintains Target Price $12
Express News | AngioDynamics, University College London Hospital Launch International Multi-Center Study On Long Term Effects Of Treatment With NanoKnife System